Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease

Neurology

Volumn 84, Issue 12, 2015, Pages 1254-1260

  Wang, Liang ^a   Benzinger, Tammie L ^a,b,c   Hassenstab, Jason ^a,c   Blazey, Tyler ^a   Owen, Christopher ^b   Liu, Jingxia ^c   Fagan, Anne M ^a   Morris, John C ^a   Ances, Beau M ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID; COGNITION; COHORT ANALYSIS; CORTICAL THICKNESS (BRAIN); CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; VERY ELDERLY; ATROPHY; BRAIN CORTEX; PATHOLOGY; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BIOMARKERS; CEREBRAL CORTEX; COHORT STUDIES; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS; PRODROMAL SYMPTOMS; TAU PROTEINS;

EID: 84925400502     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001401     Document Type: Article

References (34)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
2. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol 2013;73:472-480.
3. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci 2013;33:5553-5563.
4. Jack CR Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81:1732-1740.
5. Sperling RA, Johnson KA, Doraiswamy PM, et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013;34:822-831.
6. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based Structural Abnormality Index (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008;42:559-567.
7. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloidpositive individuals. Cereb Cortex 2009;19:497-510.
8. Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative. Biomarker-based prediction of progression in MCI. Comparison of AD signature and hippocampal volume with spinal fluid amyloid-beta and tau. Front Aging Neurosci 2013;5:55.
9. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
10. Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 2014;75:597-601.
11. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335.
12. Morris JC. The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology 1993;43:2412-2414.
13. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297.
14. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS). Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-216.
15. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
16. Pastor P, Roe CM, Villegas A, et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol 2003;54:163-169.
17. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
18. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis: II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999;9:195-207.
19. Fischl B, SerenoMI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp 1999;8:272-284.
20. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation. Automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341-355.
21. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex 2010;20:2069-2079.
22. Schott JM, Bartlett JW, Fox NC, Barnes J; Alzheimer's Disease Neuroimaging Initiative I. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 2010;68:825-834.
23. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloidbeta associated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011;70:657-661.
24. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
25. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-259.
26. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316: 750-754.
27. Knopman DS, Jack CR Jr, Wiste HJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol 2013;70:1030-1038.
28. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66:1254-1259.
29. Hedden T, Mormino EC, Amariglio RE, et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci 2012;32: 16233-16242.
30. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease. A prospective cohort study. Lancet Neurol 2013;12:357-367.
31. Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC. Toward a multifactorial model of Alzheimer disease. Neurobiol Aging 2012;33:2262-2271.
32. Chetelat G. Alzheimer disease: Abeta-independent processes: rethinking preclinical AD. Nat Rev Neurol 2013; 9:123-124.
33. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062-1064.
34. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343-349.